1. Home
  2. MAGN vs XERS Comparison

MAGN vs XERS Comparison

Compare MAGN & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magnera Corporation

MAGN

Magnera Corporation

HOLD

Current Price

$14.87

Market Cap

526.9M

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$7.15

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAGN
XERS
Founded
1864
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
526.9M
1.3B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
MAGN
XERS
Price
$14.87
$7.15
Analyst Decision
Buy
Strong Buy
Analyst Count
1
7
Target Price
$16.00
$10.43
AVG Volume (30 Days)
1.7M
2.1M
Earning Date
11-19-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,204,000,000.00
$266,137,000.00
Revenue This Year
$5.74
$44.37
Revenue Next Year
$2.51
$27.87
P/E Ratio
N/A
N/A
Revenue Growth
46.50
42.05
52 Week Low
$7.82
$3.14
52 Week High
$23.19
$10.08

Technical Indicators

Market Signals
Indicator
MAGN
XERS
Relative Strength Index (RSI) 72.12 47.42
Support Level $13.58 $6.85
Resistance Level $15.25 $7.24
Average True Range (ATR) 0.70 0.29
MACD 0.13 0.09
Stochastic Oscillator 87.93 84.94

Price Performance

Historical Comparison
MAGN
XERS

About MAGN Magnera Corporation

Magnera Corp is a supplier of a diverse portfolio of specialty materials comprised of organic and synthetic raw ingredients. The company markets its own products predominantly into stable, consumer-oriented end markets, including wipes, healthcare, adult incontinence, apparel, baby, feminine care, air filtration, and food and beverage, for disposable and durable applications. It also provides technical solutions in infrastructure markets. The company's operations are organized into two operating and reportable segments: Americas and Rest of World. It derives the majority of its revenue from the Americas, which manufactures products and components of personal care, including medical garments, wipes, dryer sheets, filtration, baby diapers and adult incontinence.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Share on Social Networks: